XML 37 R13.htm IDEA: XBRL DOCUMENT v3.20.1
Note 7 - Stockholders' Equity
3 Months Ended
Mar. 31, 2020
Notes to Financial Statements  
Share-based Payment Arrangement [Text Block]
7
.     
STOCKHOLDERS’ EQUITY
 
Common Stock
On
March 25, 2020,
the Company entered into a Securities Purchase Agreement (the “Purchase Agreement”) with
three
institutional and accredited investors (the “Investors”), pursuant to which the Company agreed to issue and sell to the Investors, in a registered direct offering (the “RDO”), an aggregate of
1,000,002
shares of the Company’s common stock at an offering price of
$3.50
per share, for gross proceeds of approximately
$3.5
million before the deduction of
$393,000
in placement agent fees and offering expenses. The shares were issued and sold by the Company pursuant to a registration statement on Form S-
3
(File
No.
333
-
235509
), which was initially filed with the Securities and Exchange Commission (the “Commission”) on
December 13, 2019
and was declared effective by the Commission on
January 3, 2020,
and the related prospectus supplement filed with the Commission on
March 27, 2020.
The closing of the RDO occurred on
March 27, 2020.
The Purchase Agreement also contains representations, warranties, indemnification and other provisions customary for transactions of this nature. Under the Purchase Agreement, (i) the Company and its subsidiaries are prohibited for a period of
30
days after the closing (subject to certain exceptions) from issuing, entering into any agreement to issue, or announcing the issuance or the proposed issuance of any shares of the Company’s common stock or any other securities that are at any time convertible into, or exercisable or exchangeable for, or otherwise entitle the holder thereof to receive, shares of the Company’s common stock and (ii) the Company is prohibited for a period of
twelve
(
12
) months after the closing (subject to certain exceptions) from effecting or entering into an agreement to effect any issuance by the Company or any of its subsidiaries of the Company’s common stock or any other securities that are at any time convertible into, or exercisable or exchangeable for, or otherwise entitle the holder thereof to receive, shares of the Company’s common stock involving a Variable Rate Transaction (as defined in the Purchase Agreement).
 
On
December 13, 2019,
the Company entered into an At The Market Offering Agreement, by and between the Company and H.C. Wainwright & Co., LLC, as agent (“H.C. Wainwright”) (the “ATM Agreement”), pursuant to which the Company
may
offer and sell, from time to time through H.C. Wainwright, shares of Common Stock, having an aggregate offering price of up to
$4.4
million (the “HCW Shares”). The offer and sale of the HCW Shares is made pursuant to a shelf registration statement on Form S-
3
and the related prospectus (File
No.
333
-
235509
). Pursuant to the ATM Agreement, H.C. Wainwright
may
sell the HCW Shares by any method permitted by law deemed to be an “at the market offering” as defined in Rule
415
of the Securities Act, including sales made by means of ordinary brokers’ transactions, including on The NASDAQ Capital Market, at market prices or as otherwise agreed with H.C. Wainwright. H.C. Wainwright will use commercially reasonable efforts consistent with its normal trading and sales practices to sell the HCW Shares from time to time, based upon instructions from the Company, including any price or size limits or other customary parameters or conditions the Company
may
impose. The Company is
not
obligated to make any sales of the HCW Shares under the ATM Agreement. The offering of HCW Shares pursuant to the ATM Agreement will terminate upon the earliest of (a) the sale of all of the HCW Shares subject to the ATM Agreement, (b) the termination of the ATM Agreement by H.C. Wainwright or the Company, as permitted therein, or (c)
August 9, 2022.
The Company will pay H.C. Wainwright a commission rate equal to
3%
of the aggregate gross proceeds from each sale of HCW Shares and have agreed to provide H.C. Wainwright with customary indemnification and contribution rights. The Company will also reimburse H.C. Wainwright for certain specified expenses in connection with entering into the ATM Agreement. As of
March 31, 2020,
the Company sold a total of
50,746
shares of Common Stock for aggregate gross proceeds of
$280,000
at an average selling price of
$5.44
per share, resulting in net proceeds of approximately
$114,000
after deducting legal expenses, audit fees, commissions and other transaction costs of approximately
$167,000.
The Company terminated the ATM Prospectus Supplement on
March 25, 2020,
but the ATM Agreement remains in effect.
 
Stock Based Compensation
The Company recorded stock-based compensation of
$67,000
and
$81,000
for the
three
months ended
March 31, 2020
and
2019,
respectively, as comprised of the following:
 
   
Three Months Ended
March 31,
 
   
2020
   
2019
 
Sales and marketing
  $
13,000
    $
12,000
 
Research and development
   
15,000
     
15,000
 
General and administrative
   
39,000
     
54,000
 
    $
67,000
    $
81,000
 
 
The following is a summary of option activity for the Company’s stock option plans:
 
   
Number of
Shares
   
Weighted-
Average
Exercise
Price
   
Weighted-
Average
Remaining
Contractual
Life
   
Aggregate
Intrinsic
Value
 
Outstanding at December 31, 2019
   
291,807
    $
13.96
     
 
     
 
 
                                 
Forfeited
   
(3,958
)   $
3.74
     
 
     
 
 
                                 
Outstanding at March 31, 2020
   
287,849
    $
14.10
     
8.06
    $
101,074
 
                                 
Vested and expected to vest at March 31, 2020
   
226,960
    $
15.70
     
7.9
    $
75,434
 
                                 
Exercisable at March 31, 2020
   
143,479
    $
20.20
     
7.61
    $
40,430
 
 
The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying awards and the quoted price of the Company’s common stock. There were
no
options exercised during the
three
months ended
March 31, 2020.
 
Warrants
A summary of warrant activity for the
three
months ended
March 31, 2020
follows:
 
   
Number of
Shares
   
Weighted-Average
Exercise Price Per
Share
 
Balance at December 31, 2019
   
1,716,066
    $
25.23
 
Warrants expired
   
--
     
--
 
Warrants exercised
   
(107,866
)   $
.53
 
                 
Outstanding at March 31, 2020
   
1,608,200
    $
26.89
 
                 
Exercisable at March 31, 2020
   
1,538,347
    $
24.47